Evidence map›Paper›PMID 37669861›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2023

Locus Coeruleus Integrity Is Linked to Response Inhibition Deficits in Parkinson's Disease and Progressive Supranuclear Palsy.

Rong Ye, Frank H Hezemans, Claire O'Callaghan, Kamen A Tsvetanov, Catarina Rua, P Simon Jones, Negin Holland, Maura Malpetti, Alexander G Murley, Roger A Barker and 4 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. The Noradrenergic Brain in Parkinson's Disease.Current neurology and neuroscience reports · 2026
    Review
  3. Review
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 6 countries.

Rong YeResearch Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230032, China ronye.uk@gmail.com.ORCID 0000-0003-2529-7755
Frank H HezemansDepartment of Clinical Neurosciences, Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, CB2 0SZ, United Kingdom.
Claire O'CallaghanDepartment of Psychiatry, University of Cambridge, Cambridge, CB2 0SZ, United Kingdom.
Kamen A TsvetanovMRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, CB2 7EF, United Kingdom.ORCID 0000-0002-3178-6363
Catarina RuaDepartment of Clinical Neurosciences, Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, CB2 0SZ, United Kingdom.
P Simon JonesDepartment of Clinical Neurosciences, Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, CB2 0SZ, United Kingdom.
Negin HollandDepartment of Clinical Neurosciences, Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, CB2 0SZ, United Kingdom.ORCID 0000-0003-3813-0882
Maura MalpettiDepartment of Clinical Neurosciences, Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, CB2 0SZ, United Kingdom.
Alexander G MurleyDepartment of Clinical Neurosciences, Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, CB2 0SZ, United Kingdom.
Roger A BarkerJohn van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, CB2 0SZ, United Kingdom.
Caroline H Williams-GrayJohn van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, CB2 0SZ, United Kingdom.
Trevor W RobbinsDepartment of Psychology, University of Cambridge, Cambridge, CB2 3EA, United Kingdom.
Luca PassamontiDepartment of Clinical Neurosciences, Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, CB2 0SZ, United Kingdom.
James B RoweDepartment of Clinical Neurosciences, Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, CB2 0SZ, United Kingdom.ORCID 0000-0001-7216-8679
University of Cambridge · GBMRC Cognition and Brain Sciences Unit · GBAnhui Medical University · CNRadboud University Nijmegen · NLThe University of Sydney · AUWellcome/MRC Cambridge Stem Cell Institute · GB

Funding

Medical Research Council MC_PC_17230Medical Research Council MC_UU_00005/12Medical Research Council MR/P01271X/1Medical Research Council MR/R007446/1Medical Research Council MR/W029235/1Parkinson's UK K-1702
6 · The paper itself

Abstract

Parkinson's disease (PD) and progressive supranuclear palsy (PSP) both impair response inhibition, exacerbating impulsivity. Inhibitory control deficits vary across individuals and are linked with worse prognosis, and lack improvement on dopaminergic therapy. Motor and cognitive control are associated with noradrenergic innervation of the cortex, arising from the locus coeruleus (LC) noradrenergic system. Here we test the hypothesis that structural variation of the LC explains response inhibition deficits in PSP and PD. Twenty-four people with idiopathic PD, 14 with PSP-Richardson's syndrome, and 24 age- and sex-matched controls undertook a stop-signal task and ultrahigh field 7T magnetization-transfer-weighted imaging of the LC. Parameters of "race models" of go- versus stop-decisions were estimated using hierarchical Bayesian methods to quantify the cognitive processes of response inhibition. We tested the multivariate relationship between LC integrity and model parameters using partial least squares. Both disorders impaired response inhibition at the group level. PSP caused a distinct pattern of abnormalities in inhibitory control with a paradoxically reduced threshold for go responses, but longer nondecision times, and more lapses of attention. The variation in response inhibition correlated with the variability of LC integrity across participants in both clinical groups. Structural imaging of the LC, coupled with behavioral modeling in parkinsonian disorders, confirms that LC integrity is associated with response inhibition and LC degeneration contributes to neurobehavioral changes. The noradrenergic system is therefore a promising target to treat impulsivity in these conditions. The optimization of noradrenergic treatment is likely to benefit from stratification according to LC integrity.

Indexed as

Parkinson DiseaseParkinsonian DisordersSupranuclear Palsy, ProgressiveBayes TheoremHumansLocus Coeruleus7T-MRIcognitive modelinglocus coeruleusParkinson's diseaseprogressive supranuclear palsyresponse inhibition

Identifiers

PMID37669861
PMCPMC10586538
OpenAlexW4386453046

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.